Get started
Novo Nordisk A/S Sponsored ADR Class BNovo Nordisk A/S Sponsored ADR Class BNovo Nordisk A/S Sponsored ADR Class B

Novo Nordisk A/S Sponsored ADR Class B

No trades
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonalsOptionsBondsETFs

Chart


Full chart

Key facts today


Novo Nordisk will launch oral Wegovy in the US in January, ahead of Eli Lilly's product, which is still awaiting FDA approval, giving Novo an early market advantage.
Novo Nordisk has updated its earnings forecast due to rising competition from cheaper GLP-1 alternatives, driven by higher demand and supply issues allowing US pharmacies to offer discounts.
Novo Nordisk's Wegovy (semaglutide) launched in India in June 2025, driving a notable rise in the weight-loss market, exceeding Rs 1,000 crore in sales soon after.
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪211.66 B‬ USD
Dividend yield (indicated)
2.56%
Price to earnings Ratio (TTM)
14.01
Basic EPS (TTM)
3.44 USD
Net income (FY)
‪14.65 B‬ USD
Revenue (FY)
‪42.12 B‬ USD
Shares float
‪3.37 B‬
Beta (1Y)
1.17

About Novo Nordisk A/S Class B


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Maziar Mike Doustdar
Website
novonordisk.com
Headquarters
Bagsværd
Founded
1923
Identifiers
3
ISINUS6701002056
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

Community forum



See all minds 

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


N
XS323295972
Novo Nordisk Finance (Netherlands) BV 4.0% 20-NOV-2045
Yield to maturity
4.27%
Maturity date
Nov 20, 2045
N
XS323295590
Novo Nordisk Finance (Netherlands) BV 3.625% 20-FEB-2038
Yield to maturity
3.84%
Maturity date
Feb 20, 2038
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037
Yield to maturity
3.76%
Maturity date
May 27, 2037
N
XS323294453
Novo Nordisk Finance (Netherlands) BV 3.375% 20-FEB-2035
Yield to maturity
3.56%
Maturity date
Feb 20, 2035
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034
Yield to maturity
3.49%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033
Yield to maturity
3.35%
Maturity date
May 27, 2033
N
XS323293716
Novo Nordisk Finance (Netherlands) BV 3.0% 20-FEB-2032
Yield to maturity
3.18%
Maturity date
Feb 20, 2032
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031
Yield to maturity
3.07%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030
Yield to maturity
3.03%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030
Yield to maturity
2.91%
Maturity date
Mar 31, 2030
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028
Yield to maturity
2.77%
Maturity date
May 27, 2028

See all NVO bonds 

ETFs


B
BBHL
BBH Select Large Cap ETF
Weight
29.00%
Market value
‪140.44 M‬
USD
PPH
VanEck Pharmaceutical ETF
Weight
6.11%
Market value
‪70.31 M‬
USD
PVAL
Putnam Focused Large Cap Value ETF
Weight
1.05%
Market value
‪52.05 M‬
USD
AVDE
Avantis International Equity ETF
Weight
0.32%
Market value
‪37.21 M‬
USD
FTHI
First Trust BuyWrite Income ETF
Weight
1.27%
Market value
‪23.72 M‬
USD
PID
Invesco International Dividend Achievers ETF
Weight
2.45%
Market value
‪21.77 M‬
USD
WCMI
First Trust WCM International Equity ETF
Weight
2.27%
Market value
‪17.90 M‬
USD
RVER
Trenchless Fund ETF
Weight
16.25%
Market value
‪17.05 M‬
USD
476070
SAMSUNG KODEX Global Obesity Treatment TOP2 Plus ETF Units
Weight
23.83%
Market value
‪12.92 M‬
USD
A
AQEC
AQE Core ETF
Weight
1.63%
Market value
‪9.83 M‬
USD
LIFE
Evolve Global Healthcare Enhanced Yield Fund
Weight
4.09%
Market value
‪9.81 M‬
USD

Explore more ETFs 

Sparks


Curated watchlists where NVO is featured.

See all sparks